6 completed, 3 terminated, 2 active not recruiting, 2 withdrawn. 14 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Completed 6, Terminated 3, Active not recruiting 2, Withdrawn 2, Unknown 1 |
| Phase 1 | 2 | Completed 1, Withdrawn 1 |
Follow Castration Levels of Testosterone: new trials by email Literature Review of Castration Levels of Testosterone trials Research Report on Castration Levels of Testosterone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer Decitabine, Enzalutamide - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 1 / Phase 2 | Withdrawn | Roswell Park Cancer Institute | 2021-04-15 | 2022-10-05 | |
| Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer Apalutamide, Stereotactic Body Radiation Therapy - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 2 | Completed | University of California, San Francisco | 26 | 2019-12-17 | 2026-01-21 |
| ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981, Nivolumab - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 2 | Terminated | Barbara Ann Karmanos Cancer Institute | 10 | 2019-11-13 | 2024-07-16 |
| sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Recombinant EphB4-HSA Fusion Protein - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 2 | Unknown | Northwestern University | 14 | 2019-09-20 | 2022-04-27 |
| Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency Carboplatin, Docetaxel, Laboratory Biomarker Analysis - ATM Gene Mutation, BRCA1 Gene Mutation | Phase 2 | Terminated | University of Washington | 18 | 2018-08-24 | 2026-08-26 |
| Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer HER2Bi-Armed Activated T Cells, Laboratory Biomarker Analysis, Pembrolizumab - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 2 | Completed | Barbara Ann Karmanos Cancer Institute | 15 | 2018-06-07 | 2023-05-03 |
| Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Durvalumab, Laboratory Biomarker Analysis - Castration Levels of Testosterone, Hormone-Resistant Prostate Cancer | Phase 2 | Withdrawn | University of Washington | 2018-05-15 | 2018-01-17 | |
| Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Abiraterone Acetate, Androgen deprivation therapy, Cabazitaxel - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 2 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 223 | 2018-04-26 | 2026-10-06 |
| ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer ESK981 - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 2 | Completed | Barbara Ann Karmanos Cancer Institute | 13 | 2018-03-08 | 2023-07-14 |
| Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Abiraterone Acetate, Apalutamide, Cabazitaxel - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 196 | 2016-05-18 | 2026-09-14 |
| Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway Carboplatin, Docetaxel, Laboratory Biomarker Analysis - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 2 | Completed | University of Washington | 14 | 2016-01-26 | 2022-11-17 |
| Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer Selinexor - Castration Levels of Testosterone, Hormone-Resistant Prostate Cancer | Phase 2 | Terminated | University of California, San Francisco | 14 | 2014-09-02 | 2018-06-26 |
| CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer Glycosylated Recombinant Human Interleukin-7, Laboratory Biomarker Analysis - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 2 | Completed | Fred Hutchinson Cancer Center | 54 | 2013-09-10 | 2019-07-09 |
| Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer Cabazitaxel, Carboplatin, Laboratory Biomarker Analysis - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 170 | 2012-07-11 | 2021-07-30 |
Prostatic Neoplasms (9) · Disease Progression (1) · Lymphadenopathy (1) · Microsatellite Instability (1)
Genital Diseases (9) · Genital Diseases, Male (9) · Genital Neoplasms, Male (9) · Male Urogenital Diseases (9) · Neoplasms (9) · Neoplasms by Site (9) · Prostatic Diseases (9) · Urogenital Diseases (9) · Urogenital Neoplasms (9) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Disease Attributes (1) · Genomic Instability (1) · Hemic and Lymphatic Diseases (1) · Lymphatic Diseases (1)
Carboplatin (4) · XRP6258 (3) · cabazitaxel (3) · Abiraterone Acetate (2) · Docetaxel (2) · Prednisone (2) · apalutamide (2) · 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one (1) · Androgen Antagonists (1) · CTLA-4 Antigen (1) · Decitabine (1) · Disulfides (1) · Immunoglobulin G (1) · Injections (1) · Ipilimumab (1)
Barbara Ann Karmanos Cancer Institute (3) · University of Washington (3) · M.D. Anderson Cancer Center (2) · University of California, San Francisco (2) · ECOG-ACRIN Cancer Research Group (1) · Fred Hutchinson Cancer Center (1) · Northwestern University (1) · Roswell Park Cancer Institute (1)
United States (14) · Puerto Rico (1)
Heather H. Cheng (2) · Abhinav Deol, M.D. (1) · Ana Aparicio (1) · Charles Ryan, MD (1) · Christos Kyriakopoulos (1) · Elisabeth Heath, M.D. (1) · Elisabeth I. Heath (1) · Gurkamal Chatta (1) · Lawrence Fong (1) · Maha H Hussain, M.D. (1) · Martin A. Cheever (1) · Michael Schweizer (1) · Paul Corn (1) · Rahul Aggarwal, MD (1)
PMID 29487219, PMID 31515154, PMID 36210299, PMID 37981040, PMID 39227508, PMID 39503807
P30CA015704 (3), P30CA022453 (3), P50CA097186 (2), P30CA016672 (1), P30CA060553 (1), U01CA154967 (1), U10CA180820 (1)